Excellergy closed a $70 million Series A to advance a portfolio of multipronged allergy therapeutics the company says could outperform current biologics such as Xolair. Company statements and a supporting scientific paper surfaced alongside the financing, which the startup will use to fund clinical development and scale operations. Investors appear to be backing a strategy of attacking allergic and immunologic diseases via combined mechanisms to achieve faster, deeper disease control.